Advanced non-small-cell lung cancer is more common in women. Credit: Robina Weermeijer / Unsplash.

The UK National Institute for Health and Care Excellence (Nice) has issued final guidance recommending using Takeda’s mobocertinib (Exkivity) to treat advanced lung cancer.

Mobocertinib has been recommended to treat epidermal growth factor receptor (EGFR) exon 20 insertion gene mutation-positive advanced non-small-cell lung cancer (NSCLC) patients who have previously received platinum-based chemotherapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The new targeted therapy will be given as four capsules a day at home.

It specifically targets the mutation to slow down the cancer cells’ growth.

The therapy was found to be well tolerated by patients in clinical trials.

See Also:

Indirect comparisons suggest that mobocertinib increases overall survival (OS) by more than three months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NICE medicines evaluation interim director Helen Knight said: “This is the first treatment approved by NICE that targets this specific gene mutation in people with advanced non-small-cell lung cancer.

“The evidence shows it not only extends people’s lives but also extends how long people have before their cancer gets worse.”

Mobocertinib was licensed through Project Orbis, which is an international programme designed to review and approve cancer drugs.

According to NICE, no standard treatment is currently available for exon 20 insertion mutation-positive NSCLC patients.

This rare and aggressive lung cancer is said to be more commonly found in women and individuals from East Asian family backgrounds, and those who do not smoke.

Last month, NICE recommended zanubrutinib (Brukinsa) as an option for the treatment of people with Waldenstrom’s macroglobulinaemia (WM).